clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2025-103-8-9-589-595clinmed-1259Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESВлияние микробиоты кишечника на развитие и течение заболеваний у пациентов с хронической болезнью почек в сочетании с сердечно-сосудистой патологиейInfluence of intestinal microbiota on the development and course of diseases in patients with chronic kidney disease in combination with cardiovascular pathologyhttps://orcid.org/0000-0002-8625-812XКлассоваА. Т.KlassovaA. T.

Классова Айгуль Тахировна — ассистент кафедры поликлинической терапии

Ставрополь 

Aigul T. Klassova — Assistant of the Department of Outpatient Therapy 

Stavropol 

https://orcid.org/0000-0002-8835-537XАграновичН. В.AgranovichN. V.

Агранович Надежда Владимировна — д-р мед. наук, профессор, заведующая кафедрой поликлинической терапии

Ставрополь 

Nadezhda V. Agranovich — Doctor of Medical Sciences, Professor, Head of the Department of Outpatient Therapy

Stavropol 

https://orcid.org/0000-0002-9308-6784АнопченкоА. С.AnopchenkoA. S.

Анопченко Алена Сергеевна — канд. мед. наук, доцент кафедры поликлинической терапии

Ставрополь 

Alena S. Anopchenko — Candidate of Medical Sciences, Docent of the Department of Outpatient Therapy

Stavropol 

a.anopchenko@mail.ruАграновичА. О.AgranovichA. O.

Агранович Андрей Олегович — канд. мед. наук, ассистент кафедры неврологии и нейрореабилитации

Ставрополь 

Andrey O. Agranovich — Candidate of Medical Sciences, Assistant of the Department of Neurology and Neurorehabilitation

Stavropol 

ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава РоссииРоссияStavropol State Medical University of the Ministry of Health of RussiaRussian Federation2025270120261038-9589595Copyright © Классова А.Т., Агранович Н.В., Анопченко А.С., Агранович А.О., 20262026Классова А.Т., Агранович Н.В., Анопченко А.С., Агранович А.О.Klassova A.T., Agranovich N.V., Anopchenko A.S., Agranovich A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/1259

Состав микробиоты кишечника связан с протеканием таких заболеваний, как хроническая болезнь почек (ХБП), артериальная гипертензия (АГ) и ишемическая болезнь сердца (ИБС). У пациентов с ХБП, АГ и ИБС часто наблюдаются изменения в составе микробиоты, которые могут быть связаны с увеличением воспалительных процессов, нарушением обмена веществ и другими факторами, способствующими прогрессированию этих заболеваний. Микробиота кишечника может меняться в ответ на лечение, улучшая состояние пациента. В данном обзоре отмечен уремический токсин, продуцируемый кишечной микробиотой — фенилацетилглутамин (ФАГ), который может стать отличным показателем вероятности рестеноза или гиперплазии интимы в стенте. Увеличение числа бактерий рода Lachnospira может привести к послеоперационным осложнениям после аортокоронарного шунтирования.

The composition of the intestinal microbiota is associated with the course of diseases such as chronic kidney disease, arterial hypertension and coronary heart disease. Patients with CKD, hypertension and coronary artery disease often experience changes in the composition of the microbiota, which may be associated with an increase in inflammatory processes, metabolic disorders and other factors that contribute to the progression of these diseases. The gut microbiota can change in response to treatment, improving the patient’s condition. This review highlights a uremic toxin produced by the gut microbiota, phenylacetylglutamine (PAG), which may be an excellent indicator of the likelihood of in-stent restenosis or hyperplasia. An increase in the number of bacteria of the genus Lachnospira can lead to postoperative complications after coronary artery bypass grafting.

микробиота кишечникахроническая болезнь почекартериальная гипертензияишемическая болезнь почекстентированиеаортокоронарное шунтированиеишемическая болезнь сердцаintestinal microbiotachronic kidney diseasearterial hypertensionischemic kidney diseasestentingcoronary artery bypass graftingcoronary heart diseaseReferencesMiyauchi E. et al. The impact of the gut microbiome on extraintestinal autoimmune diseases. Nat. Rev. Immunol. 2023;23(1):9– 23. DOI: 10.1038/s41577-022-00727-yMiyauchi E. et al. The impact of the gut microbiome on extraintestinal autoimmune diseases. Nat. Rev. Immunol. 2023;23(1):9– 23. DOI: 10.1038/s41577-022-00727-yMcCulloch J.A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 2022;28(3):545–556. DOI: 10.1038/s41591-022-01698-2McCulloch J.A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 2022;28(3):545–556. DOI: 10.1038/s41591-022-01698-2World health statistics 2023: monitoring health for the SDGs, sustainable development goals. [Electronic resource]. URL: https://www.who.int/publications/i/item/9789240074323World health statistics 2023: monitoring health for the SDGs, sustainable development goals. [Electronic resource]. URL: https://www.who.int/publications/i/item/9789240074323Sircana A. et al. Gut microbiota, hypertension and chronic kidney disease: Recent advances. Pharmacological Research. 2019;144:390– 408. DOI: 10.1016/j.phrs.2018.01.013Sircana A. et al. Gut microbiota, hypertension and chronic kidney disease: Recent advances. Pharmacological Research. 2019;144:390– 408. DOI: 10.1016/j.phrs.2018.01.013Ryabov V.V. et al. Coronary stent technology and the role of inflammation in the atherogenesis: problems and prospects. Bûll. sib. med. 2021;20(1):200–212. DOI: 10.20538/1682-0363-2021-1-200-212Ryabov V.V. et al. Coronary stent technology and the role of inflammation in the atherogenesis: problems and prospects. Bûll. sib. med. 2021;20(1):200–212. DOI: 10.20538/1682-0363-2021-1-200-212Wong J. et al. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am. J. Nephrol. 2014;39(3):230–237. DOI: 10.1159/000360010Wong J. et al. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am. J. Nephrol. 2014;39(3):230–237. DOI: 10.1159/000360010Jiang S. et al. A reduction in the butyrate producing species Roseburia spp. and Faecalibacterium prausnitzii is associated with chronic kidney disease progression. Antonie van Leeuwenhoek. 2016;109(10):1389–1396. DOI: 10.1007/s10482-016-0737-yJiang S. et al. A reduction in the butyrate producing species Roseburia spp. and Faecalibacterium prausnitzii is associated with chronic kidney disease progression. Antonie van Leeuwenhoek. 2016;109(10):1389–1396. DOI: 10.1007/s10482-016-0737-yYang Z. et al. Gut microbiota and hypertension: association, mechanisms and treatment. Clinical and Experimental Hypertension. 2023;45(1):2195135. DOI: 10.1080/10641963.2023.2195135Yang Z. et al. Gut microbiota and hypertension: association, mechanisms and treatment. Clinical and Experimental Hypertension. 2023;45(1):2195135. DOI: 10.1080/10641963.2023.2195135Yang T. et al. The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease. Nat. Rev. Nephrol. 2018;14(7):442–456. DOI: 10.1038/s41581-018-0018-2Yang T. et al. The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease. Nat. Rev. Nephrol. 2018;14(7):442–456. DOI: 10.1038/s41581-018-0018-2Li J. et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5(1):14. DOI: 10.1186/s40168-016-0222-xLi J. et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5(1):14. DOI: 10.1186/s40168-016-0222-xDinakis E. et al. Association Between the Gut Microbiome and Their Metabolites With Human Blood Pressure Variability. Hypertension. 2022;79(8):1690–1701. DOI: 10.1161/HYPERTENSIONAHA.122.19350Dinakis E. et al. Association Between the Gut Microbiome and Their Metabolites With Human Blood Pressure Variability. Hypertension. 2022;79(8):1690–1701. DOI: 10.1161/HYPERTENSIONAHA.122.19350Mushtaq N. et al. Molecular characterization of alterations in the intestinal microbiota of patients with grade 3 hypertension. Int. J. Mol. Med. 2019. DOI: 10.3892/ijmm.2019.4235Mushtaq N. et al. Molecular characterization of alterations in the intestinal microbiota of patients with grade 3 hypertension. Int. J. Mol. Med. 2019. DOI: 10.3892/ijmm.2019.4235Larabi A., Barnich N., Nguyen H.T.T. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2020;16(1):38–51. DOI: 10.1080/15548627.2019.1635384Larabi A., Barnich N., Nguyen H.T.T. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2020;16(1):38–51. DOI: 10.1080/15548627.2019.1635384Sircana A. et al. Gut microbiota, hypertension and chronic kidney disease: Recent advances. Pharmacological Research. 2019;144:390–408. DOI: 10.1016/j.phrs.2018.01.013Sircana A. et al. Gut microbiota, hypertension and chronic kidney disease: Recent advances. Pharmacological Research. 2019;144:390–408. DOI: 10.1016/j.phrs.2018.01.013Wilck N. et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature. 2017;551(7682):585–589. DOI: 10.1038/nature24628Wilck N. et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature. 2017;551(7682):585–589. DOI: 10.1038/nature24628Yan X. et al. Intestinal Flora Modulates Blood Pressure by Regulating the Synthesis of Intestinal-Derived Corticosterone in High Salt-Induced Hypertension. Circulation Research. 2020;126(7):839–853. DOI: 10.1161/CIRCRESAHA.119.316394Yan X. et al. Intestinal Flora Modulates Blood Pressure by Regulating the Synthesis of Intestinal-Derived Corticosterone in High SaltInduced Hypertension. Circulation Research. 2020;126(7):839–853. DOI: 10.1161/CIRCRESAHA.119.316394Zhu Q. et al. Dysbiosis signatures of gut microbiota in coronary artery disease. Physiological Genomics. 2018;50(10):893–903. DOI: 10.1152/physiolgenomics.00070.2018Zhu Q. et al. Dysbiosis signatures of gut microbiota in coronary artery disease. Physiological Genomics. 2018;50(10):893–903. DOI: 10.1152/physiolgenomics.00070.2018Fan Y. et al. Microbiota-related metabolites fueling the understanding of ischemic heart disease. Imeta. 2023;2(2):e94. DOI: 10.1002/imt2.94Fan Y. et al. Microbiota-related metabolites fueling the understanding of ischemic heart disease. Imeta. 2023;2(2):e94. DOI: 10.1002/imt2.94Yoshida N., Yamashita T., Hirata K. Gut Microbiome and Cardiovascular Diseases. Diseases. 2018;6(3):56. DOI: 10.3390/diseases6030056Yoshida N., Yamashita T., Hirata K. Gut Microbiome and Cardiovascular Diseases. Diseases. 2018;6(3):56. DOI: 10.3390/diseases6030056Jin M. et al. The role of intestinal microbiota in cardiovascular disease. J. Cell. Mol. Med. 2019;23(4):2343–2350. DOI: 10.1111/jcmm.14195Jin M. et al. The role of intestinal microbiota in cardiovascular disease. J. Cell. Mol. Med. 2019;23(4):2343–2350. DOI: 10.1111/jcmm.14195Horvath A. et al. Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study. Eur. J. Nutr. 2020;59(7):2969–2983. DOI: 10.1007/s00394-019-02135-wHorvath A. et al. Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study. Eur. J. Nutr. 2020;59(7):2969–2983. DOI: 10.1007/s00394-019-02135-wRobles‐Vera I. et al. Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects. British J. Pharmacology. 2020;177(9):2006–2023. DOI: 10.1111/bph.14965Robles‐Vera I. et al. Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects. British J. Pharmacology. 2020;177(9):2006–2023. DOI: 10.1111/bph.14965Pribylova N.N. et al. Endothelial dysfunction, vascular stiffness and their correction with perindopril, losartan in patients with ischemic heart disease, arterial hypertension and chronic kidney disease after coronary stenting. Humans and their Health. 2022;25(3):15–23. DOI: 10.21626/vestnik/2022-3/02Pribylova N.N. et al. Endothelial dysfunction, vascular stiffness and their correction with perindopril, losartan in patients with ischemic heart disease, arterial hypertension and chronic kidney disease after coronary stenting. Humans and their Health. 2022;25(3):15–23. DOI: 10.21626/vestnik/2022-3/02Santisteban M.M. et al. Hypertension-Linked pathophysiological alterations in the gut. Circulation Research. 2017;120(2):312–323. DOI: 10.1161/CIRCRESAHA.116.309006Santisteban M.M. et al. Hypertension-Linked pathophysiological alterations in the gut. Circulation Research. 2017;120(2):312–323. DOI: 10.1161/CIRCRESAHA.116.309006Yoo H.H. et al. Effects of orally administered antibiotics on the bioavailability of amlodipine: gut microbiota-mediated drug interaction. Journal of Hypertension. 2016;34(1):156–162. DOI: 10.1097/HJH.0000000000000773Yoo H.H. et al. Effects of orally administered antibiotics on the bioavailability of amlodipine: gut microbiota-mediated drug interaction. Journal of Hypertension. 2016;34(1):156–162. DOI: 10.1097/HJH.0000000000000773Song Y. et al. Gut microbiota-dependent phenylacetylglutamine in cardiovascular disease: current knowledge and new insights. Front. Med. 2024;18(1):31–45. DOI: 10.1007/s11684-024-1055-9Song Y. et al. Gut microbiota-dependent phenylacetylglutamine in cardiovascular disease: current knowledge and new insights. Front. Med. 2024;18(1):31–45. DOI: 10.1007/s11684-024-1055-9Liu M. et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur. Rev. Med. Pharmacol. Sci. 2014;18(19):2918– 2926. PMID: 25339487Liu M. et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur. Rev. Med. Pharmacol. Sci. 2014;18(19):2918– 2926. PMID: 25339487Hsu C.-N., Tain Y.-L. Chronic kidney disease and gut microbiota: what is their connection in early life? Int. J. Mol. Sci. 2022;23(7):3954. DOI: 10.3390/ijms23073954Hsu C.-N., Tain Y.-L. Chronic kidney disease and gut microbiota: what is their connection in early life? Int. J. Mol. Sci. 2022;23(7):3954. DOI: 10.3390/ijms23073954Liu Y. et al. Phenylacetylglutamine is associated with the degree of coronary atherosclerotic severity assessed by coronary computed tomographic angiography in patients with suspected coronary artery disease. Atherosclerosis. 2021;333:75–82. DOI: 10.1016/j.atherosclerosis.2021.08.029Liu Y. et al. Phenylacetylglutamine is associated with the degree of coronary atherosclerotic severity assessed by coronary computed tomographic angiography in patients with suspected coronary artery disease. Atherosclerosis. 2021;333:75–82. DOI: 10.1016/j.atherosclerosis.2021.08.029Ottosson F. et al. The gut microbiota-related metabolite phenylacetyl glutamine associates with increased risk of incident coronary artery disease. Journal of Hypertension. 2020;38(12):2427–2434. DOI: 10.1097/HJH.0000000000002569Ottosson F. et al. The gut microbiota-related metabolite phenylacetyl glutamine associates with increased risk of incident coronary artery disease. Journal of Hypertension. 2020;38(12):2427–2434. DOI: 10.1097/HJH.0000000000002569Menni C. et al. Gut microbial diversity is associated with lower arterial stiffness in women. European Heart Journal. 2018;39(25):2390– 2397. DOI: 10.1093/eurheartj/ehy226Menni C. et al. Gut microbial diversity is associated with lower arterial stiffness in women. European Heart Journal. 2018;39(25):2390– 2397. DOI: 10.1093/eurheartj/ehy226Yu F. et al. Phenylacetylglutamine, a Novel Biomarker in Acute Ischemic Stroke. Front. Cardiovasc. Med. 2021;8:798765. DOI: 10.3389/fcvm.2021.798765Yu F. et al. Phenylacetylglutamine, a Novel Biomarker in Acute Ischemic Stroke. Front. Cardiovasc. Med. 2021;8:798765. DOI: 10.3389/fcvm.2021.798765Azab S.M. et al. Serum metabolic signatures of chronic limb-threatening ischemia in patients with peripheral artery disease. JCM. 2020;9(6):1877. DOI: 10.3390/jcm9061877Azab S.M. et al. Serum metabolic signatures of chronic limb-threatening ischemia in patients with peripheral artery disease. JCM. 2020;9(6):1877. DOI: 10.3390/jcm9061877Liu Y. et al. Phenylacetylglutamine is associated with the degree of coronary atherosclerotic severity assessed by coronary computed tomographic angiography in patients with suspected coronary artery disease. Atherosclerosis. 2021;333:75–82. DOI: 10.1016/j.atherosclerosis.2021.08.029Liu Y. et al. Phenylacetylglutamine is associated with the degree of coronary atherosclerotic severity assessed by coronary computed tomographic angiography in patients with suspected coronary artery disease. Atherosclerosis. 2021;333:75–82. DOI: 10.1016/j.atherosclerosis.2021.08.029Fu Y. et al. Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis. Y. Fu et al. Front. Cardiovasc. Med. 2022;9:944155. DOI: 10.3389/fcvm.2022.944155Fu Y. et al. Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis. Y. Fu et al. Front. Cardiovasc. Med. 2022;9:944155. DOI: 10.3389/fcvm.2022.944155Fang C. et al. Dysbiosis of gut microbiota and metabolite phenylacetylglutamine in coronary artery disease patients with stent stenosis. Front. Cardiovasc. Med. 2022;9:832092. DOI: 10.1111/jcmm.15959Fang C. et al. Dysbiosis of gut microbiota and metabolite phenylacetylglutamine in coronary artery disease patients with stent stenosis. Front. Cardiovasc. Med. 2022;9:832092. DOI: 10.1111/jcmm.15959Li J. et al. Shifts in gut microbiome and metabolome are associated with risk of recurrent atrial fibrillation. J. Cellular. Molecular. Medi. 2020;24(22):13356–13369. DOI: 10.3389/fcvm.2022.832092Li J. et al. Shifts in gut microbiome and metabolome are associated with risk of recurrent atrial fibrillation. J. Cellular. Molecular. Medi. 2020;24(22):13356–13369. DOI: 10.3389/fcvm.2022.832092Zuo K. et al. Disordered gut microbiota and alterations in metabolic patterns are associated with atrial fibrillation. GigaScience. 2019;8(6):giz058. DOI: 10.1093/gigascience/giz058Zuo K. et al. Disordered gut microbiota and alterations in metabolic patterns are associated with atrial fibrillation. GigaScience. 2019;8(6):giz058. DOI: 10.1093/gigascience/giz058Fujimoto D. et al. The relationship between unique gut microbiome-derived lipid metabolites and subsequent revascularization in patients who underwent percutaneous coronary intervention. Atherosclerosis. 2023;375:1–8. DOI: 10.1016/j.atherosclerosis.2023.05.001Fujimoto D. et al. The relationship between unique gut microbiome-derived lipid metabolites and subsequent revascularization in patients who underwent percutaneous coronary intervention. Atherosclerosis. 2023;375:1–8. DOI: 10.1016/j.atherosclerosis.2023.05.001Wang Y. et al. Gut microbiota in patients with postoperative atrial fibrillation undergoing off-pump coronary bypass graft surgery. J. Clin. Med. 2023;12(4):1493. DOI: 10.3390/jcm12041493Wang Y. et al. Gut microbiota in patients with postoperative atrial fibrillation undergoing off-pump coronary bypass graft surgery. J. Clin. Med. 2023;12(4):1493. DOI: 10.3390/jcm12041493Liu Y. et al. Gut microbiota metabolism disturbance is associated with postoperative atrial fibrillation after coronary artery bypass grafting. J. Cardiovasc. Health. 2024;1(1):5. DOI: 10.1038/s44325-024-00003-zLiu Y. et al. Gut microbiota metabolism disturbance is associated with postoperative atrial fibrillation after coronary artery bypass grafting. J. Cardiovasc. Health. 2024;1(1):5. DOI: 10.1038/s44325-024-00003-z

The authors declare that there are no conflicts of interest present.